← 產業報告目錄

Molecular Diagnostics Market by Product & Service (Kits, Instruments, Software), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (PCR, NGS, ISH), and Application (Infectious (Hepatitis, HIV, HAI, Flu), Cancer (Breast, Lung)) - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2025-09-09頁數 540報告編號 MD2521

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The molecular diagnostics market is valued at an estimated USD 19.48 billion in 2025 and is projected to reach USD 30.74 billion by 2030 at a CAGR of 9.6% during the forecast period. Molecular diagnostics plays a vital role in modern healthcare by enabling disease detection at the molecular and genetic level. These technologies offer high sensitivity and specificity, allowing for the early identification of pathogens and genetic abnormalities. Continuous technological advancements, such as faster processing times, automated platforms, and improved assay designs, have significantly enhanced the reliability and accessibility of molecular tests. These innovations are significant in supporting large-scale testing efforts across diverse healthcare settings. Moreover, in countries like India, government and private sector initiatives contribute to increased public awareness and greater access to diagnostic and treatment services. Such efforts are expected to accelerate the adoption of molecular diagnostics in the coming years. “By sample type, the blood, serum, and plasma segment dominated the molecular diagnostics market in 2024.” By sample type, the molecular diagnostics market is segmented into blood, serum & plasma; urine; and other sample types. The blood, serum, and plasma segment accounted for the largest share of the market in 2024. This is attributed to the high sensitivity and specificity these sample types offer in detecting a wide range of diseases, including viral infections and oncological conditions. Their stability during transportation and storage makes them ideal for centralized laboratories and point-of-care settings. Additionally, the growing adoption of personalized medicine and increased use of biomarkers in clinical decision-making fuel the demand for blood-based molecular testing. These advantages collectively position the segment for continued strong growth. “By technology, the DNA sequencing & next-generation sequencing (NGS) segment is projected to achieve the highest growth during the forecast period.” By technology, the molecular diagnostics market is bifurcated into polymerase chain reaction (PCR), isothermal nucleic acid amplification technology, in situ hybridization, DNA sequencing & next-generation sequencing (NGS), DNA microarrays, and other technologies. The DNA sequencing & next-generation sequencing (NGS) segment is projected to witness the highest growth during the forecast period. This surge is driven by their expanding use in detecting genetic mutations, identifying infectious agents, and guiding personalized treatment plans. The increasing turnaround time and data accuracy improvements have also broadened their adoption in research and clinical settings. Moreover, NGS is gaining traction due to its high-throughput capabilities and utility in comprehensive genomic profiling. As precision medicine continues to advance, the demand for sequencing-based diagnostics is set to rise significantly. “Asia Pacific is projected to be the fastest-growing regional market during the forecast period.” The market for molecular diagnostics is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is projected to witness the highest growth in the global molecular diagnostics market during the forecast period. This growth is supported by the rising healthcare investments, growing awareness of early disease detection, and increasing adoption of advanced diagnostic technologies across emerging economies. Countries such as China, India, and South Korea are experiencing rapid improvements in healthcare infrastructure and laboratory capacity. In addition, government initiatives aimed at strengthening infectious disease surveillance and expanding access to molecular testing are contributing to market growth. The large patient population and rising demand for personalized healthcare solutions further reinforce the region’s growth potential. Break-up of primary participant profiles in the molecular diagnostics market: • By Company Type: Tier 1 – 40%, Tier 2 –30%, and Tier 3 – 30% • By Designation: C-level – 27%, Director-level – 18%, and Others – 55% • By Region: North America – 51%, Europe – 21%, Asia Pacific – 18%, Latin America – 6%, and Middle East & Africa – 4% The key players in the molecular diagnostics market are Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Illumina, Inc. (US), Abbott Laboratories (US), bioMérieux (France), Thermo Fisher Scientific Inc. (US), QIAGEN N.V. (Netherlands), Revvity, Inc. (US), Myriad Genetics, Inc. (US), Siemens Healthineers AG (Germany), Becton, Dickinson and Company (BD) (US), Grifols, S.A. (Spain), QuidelOrtho Corporation (US), DiaSorin S.p.A. (Italy), Exact Sciences Corporation (US), Genetic Signatures (Australia), Agilent Technologies, Inc. (US), MDxHealth (Belgium), Biocartis (Belgium), Bruker (US), TBG Diagnostics Limited (Australia), Amoy Diagnostics Co., Ltd. (China), Vela Diagnostics (Singapore), Molbio Diagnostics Pvt. Ltd. (India), geneOmbio Technologies (India), Savyon Diagnostics (Israel), and Uniogen OY (Finland). Research Coverage: This research report categorizes the molecular diagnostics market by product & service (reagents & kits, instruments, and services), test type (lab tests and PoC tests), sample type (blood, serum & plasma; urine; and other sample types), technology (polymerase chain reaction (PCR), isothermal nucleic acid amplification technology, in situ hybridization, DNA sequencing & next-generation sequencing (NGS), DNA microarrays, and other technologies), application {infectious disease diagnostics [hepatitis (hepatitis B, hepatitis C & other hepatitis diseases), sexually transmitted diseases (HIV, CT/NG, HPV, syphilis, & other sexually transmitted diseases), respiratory infectious diseases (tuberculosis, influenza, pharyngitis, & other respiratory infectious diseases), hospital-acquired infections, vector-borne diseases, and other infectious diseases], oncology testing (breast cancer, colorectal cancer, lung cancer, prostate cancer, and other cancers), genetic testing and other applications}, technique (multiplex testing and singleplex testing), clinical application (diagnostic and screening), end user (hospitals & clinics, diagnostic laboratories, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the molecular diagnostics market. A thorough analysis of the key industry players provides insights into their business overview, solutions, key strategies, acquisitions, and agreements. This report also covers a competitive analysis of upcoming startups in the molecular diagnostics market ecosystem. Reasons to buy this report: The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall molecular diagnostics market and the subsegments. It will also help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report will help stakeholders understand the market pulse, providing information on key market drivers, restraints, opportunities, and challenges. The report provides insights on the following pointers: • Analysis of key drivers [Increasing prevalence of infectious diseases and cancer, growing R&D funding, surge in technological advancements in molecular diagnostics, and rising use of point-of-care (PoC) diagnostic tests], opportunities (Growing significance of companion diagnostics and increasing growth opportunities in emerging economies), restraints (Inadequate reimbursements and high cost of molecular diagnostic instruments), and challenges (Changing regulatory landscape, operational barriers and labor shortage, and introduction of alternative technologies) influencing the growth of the molecular diagnostics market. • Product Development/Innovation: Detailed insights into upcoming technologies, research & development activities, and new product launches in the molecular diagnostics market • Market Development: Comprehensive information about lucrative markets across varied regions • Market Diversification: Exhaustive information about products, untapped geographies, recent developments, and investments in the molecular diagnostics market • Competitive Assessment: In-depth assessment of market share, growth strategies, product offerings of leading players like Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), Illumina, Inc. (US), bioMérieux (France), and Hologic, Inc. (US)
目錄 Table of Contents
1 INTRODUCTION 48 1.1 STUDY OBJECTIVES 48 1.2 MARKET DEFINITION 48 1.3 STUDY SCOPE 49 1.3.1 MARKET SEGMENTATION 49 1.3.2 REGIONAL SCOPE 50 1.4 INCLUSIONS & EXCLUSIONS 50 1.5 YEARS CONSIDERED 51 1.6 CURRENCY CONSIDERED 52 1.7 KEY STAKEHOLDERS 52 1.8 SUMMARY OF CHANGES 52 2 RESEARCH METHODOLOGY 53 2.1 RESEARCH DATA 53 2.1.1 SECONDARY DATA 53 2.1.1.1 Key secondary sources 54 2.1.1.2 Key data from secondary sources 54 2.1.2 PRIMARY DATA 55 2.1.2.1 Key primary sources 56 2.1.2.2 Key data from primary sources 56 2.1.2.3 Key industry insights 58 2.1.2.4 Breakdown of primary interviews 59 2.2 MARKET SIZE ESTIMATION 59 2.2.1 BOTTOM-UP APPROACH 60 2.2.1.1 Approach 1: Company revenue estimation approach 60 2.2.1.2 Approach 2: Presentation of companies and primary interviews 60 2.2.1.3 Growth forecast 61 2.2.1.4 CAGR projections 61 2.2.2 TOP-DOWN APPROACH 61 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 63 2.4 MARKET SHARE ASSESSMENT 64 2.5 RESEARCH ASSUMPTIONS 64 2.5.1 PARAMETRIC ASSUMPTIONS 64 2.6 RESEARCH LIMITATIONS 64 2.7 RISK ASSESSMENT 65 3 EXECUTIVE SUMMARY 66   4 PREMIUM INSIGHTS 73 4.1 MOLECULAR DIAGNOSTICS MARKET OVERVIEW 73 4.2 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 73 4.3 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2025 VS. 2030 74 4.4 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2025 VS. 2030 74 4.5 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030 75 4.6 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2025 VS. 2030 75 4.7 MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2025 VS. 2030 76 4.8 MOLECULAR DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2025 VS. 2030 76 4.9 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 77 4.10 MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 77 5 MARKET OVERVIEW 78 5.1 INTRODUCTION 78 5.2 MARKET DYNAMICS 78 5.2.1 DRIVERS 79 5.2.1.1 Increasing prevalence of infectious diseases and cancer 79 5.2.1.2 Growing R&D funding 81 5.2.1.3 Surge in technological advancements 82 5.2.1.4 Rising use of point-of-care diagnostic tests 83 5.2.2 RESTRAINTS 84 5.2.2.1 Inadequate reimbursements 84 5.2.2.2 High cost of molecular diagnostic instruments 84 5.2.3 OPPORTUNITIES 85 5.2.3.1 Growing significance of companion diagnostics 85 5.2.3.2 Increasing growth opportunities in emerging economies 85 5.2.4 CHALLENGES 86 5.2.4.1 Changing regulatory landscape 86 5.2.4.2 Operational barriers and labor shortage 86 5.2.4.3 Introduction of alternative technologies 86 5.3 PRICING ANALYSIS 87 5.3.1 AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTIC PRODUCTS 88 5.3.2 AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTIC REAGENTS & KITS, BY KEY PLAYER 88 5.3.3 AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTIC PRODUCTS, BY REGION 89 5.4 PATENT ANALYSIS 90 5.4.1 LIST OF MAJOR PATENTS 91 5.5 VALUE CHAIN ANALYSIS 91 5.6 SUPPLY CHAIN ANALYSIS 93   5.7 HS CODES 94 5.7.1 IMPORT SCENARIO (HS CODE 3822) 94 5.7.2 EXPORT SCENARIO (HS CODE 3822) 95 5.8 ECOSYSTEM ANALYSIS 96 5.9 PORTER’S FIVE FORCES ANALYSIS 97 5.9.1 THREAT FROM NEW ENTRANTS 98 5.9.2 THREAT FROM SUBSTITUTES 98 5.9.3 BARGAINING POWER OF BUYERS 98 5.9.4 BARGAINING POWER OF SUPPLIERS 98 5.9.5 INTENSITY OF COMPETITIVE RIVALRY 99 5.10 REGULATORY LANDSCAPE 99 5.10.1 REGULATORY FRAMEWORK 99 5.10.1.1 North America 99 5.10.1.1.1 US 99 5.10.1.1.2 Canada 99 5.10.1.2 Europe 99 5.10.1.2.1 Germany 100 5.10.1.2.2 UK 100 5.10.1.2.3 France 101 5.10.1.2.4 Italy 101 5.10.1.3 Asia Pacific 101 5.10.1.3.1 China 101 5.10.1.3.2 Japan 101 5.10.1.3.3 India 102 5.10.1.4 Latin America 102 5.10.1.4.1 Brazil 102 5.10.1.4.2 Mexico 103 5.10.1.5 Middle East 103 5.10.1.5.1 Africa 103 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103 5.11 TECHNOLOGY ANALYSIS 105 5.11.1 KEY TECHNOLOGIES 105 5.11.1.1 Polymerase chain reaction 105 5.11.2 COMPLEMENTARY TECHNOLOGIES 106 5.11.2.1 Microarrays 106 5.11.3 ADJACENT TECHNOLOGIES 107 5.11.3.1 Next-generation sequencing 107 5.12 KEY CONFERENCES & EVENTS, 2025–2026 107 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 108   5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 109 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 109 5.14.2 BUYING CRITERIA 110 5.15 INVESTMENT AND FUNDING SCENARIO 110 5.16 CASE STUDY ANALYSIS 111 5.16.1 CASE STUDY 1: USING MOLECULAR DIAGNOSTICS TO IDENTIFY ATYPICAL RESPIRATORY INFECTION 111 5.16.2 CASE STUDY 2: IMPLEMENTING RAPID PCR TESTING TO IMPROVE NOROVIRUS DIAGNOSIS AND BED MANAGEMENT 112 5.16.3 CASE STUDY 3: RAPID PCR TESTING STREAMLINED EMERGENCY CARE AND SURGICAL RESOURCE MANAGEMENT IN GERMAN HOSPITAL 112 5.17 IMPACT OF AI/GENERATIVE AI ON MOLECULAR DIAGNOSTICS MARKET 113 5.17.1 INTRODUCTION 113 5.17.2 MARKET POTENTIAL OF AI 113 5.17.2.1 Key use cases 114 5.17.3 IMPLEMENTATION OF AI BY KEY COMPANIES 114 5.17.4 FUTURE OF AI IN MOLECULAR DIAGNOSTICS MARKET 115 5.18 US 2025 TARIFF 115 5.18.1 INTRODUCTION 115 5.18.2 KEY TARIFF RATES 116 5.18.3 PRICE IMPACT ANALYSIS 116 5.18.4 IMPACT ON REGION 117 5.18.4.1 North America 117 5.18.4.2 Europe 117 5.18.4.3 Asia Pacific 117 5.18.5 IMPACT ON END-USE INDUSTRIES 117 5.18.5.1 Hospitals & clinics 117 5.18.5.2 Diagnostic laboratories 118 6 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 119 6.1 INTRODUCTION 120 6.2 REAGENTS & KITS 120 6.2.1 INCREASING AWARENESS ABOUT EARLY DISEASE DETECTION TO PROPEL MARKET 120 6.3 INSTRUMENTS 124 6.3.1 RISING NEED FOR QUICK AND ACCURATE TEST RESULTS TO BOOST MARKET 124 6.4 SERVICES & SOFTWARE 128 6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE MARKET 128   7 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE 131 7.1 INTRODUCTION 132 7.2 LAB TESTS 132 7.2.1 INCREASING NEED FOR AUTOMATION AND EFFICIENT DISEASE TESTING TO DRIVE MARKET 132 7.3 POC TESTS 136 7.3.1 INCREASED INVESTMENT BY PUBLIC HEALTH AGENCIES AND GOVERNMENTS TO BOOST MARKET 136 8 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE 140 8.1 INTRODUCTION 141 8.2 BLOOD, SERUM, AND PLASMA 141 8.2.1 INCREASING UTILIZATION IN GENETIC TESTING, INFECTIOUS DISEASE DIAGNOSIS, AND CANCER DIAGNOSTICS TO PROPEL MARKET 141 8.3 URINE 145 8.3.1 NEED FOR NON-INVASIVE AND EASY SAMPLE COLLECTION TECHNIQUE TO FUEL MARKET 145 8.4 OTHER SAMPLE TYPES 148 9 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY 152 9.1 INTRODUCTION 153 9.2 POLYMERASE CHAIN REACTION 154 9.2.1 RISING USE IN PROTEOMICS AND GENOMICS TO AID GROWTH 154 9.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY 158 9.3.1 NEED FOR PROMPT DIAGNOSIS TO STIMULATE GROWTH 158 9.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING 161 9.4.1 GROWING TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET 161 9.5 IN SITU HYBRIDIZATION 165 9.5.1 RISING APPLICATIONS IN DIAGNOSING CHROMOSOMAL ABNORMALITIES AND GENE MAPPING TO BOOST MARKET 165 9.6 DNA MICROARRAYS 168 9.6.1 SURGE IN ADVANCEMENTS IN DESIGN, DENSITY, AND DETECTION TECHNIQUES TO FUEL MARKET 168 9.7 OTHER TECHNOLOGIES 172 10 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION 176 10.1 INTRODUCTION 177 10.2 INFECTIOUS DISEASE DIAGNOSTICS 177 10.2.1 SEXUALLY TRANSMITTED DISEASES 181 10.2.1.1 CT/NG 185 10.2.1.1.1 Growing development of novel assays to boost market 185 10.2.1.2 HIV 188 10.2.1.2.1 Increasing blood transfusions and blood donations to propel market 188 10.2.1.3 HPV 191 10.2.1.3.1 Rising cases of cervical cancer to augment growth 191 10.2.1.4 Syphilis 194 10.2.1.4.1 Growing demand for affordable and rapid molecular diagnostic solutions to drive market 194 10.2.1.5 Other sexually transmitted diseases 197 10.2.2 HEPATITIS 200 10.2.2.1 Hepatitis B 203 10.2.2.1.1 Need for ongoing management and monitoring of virus to drive market 203 10.2.2.2 Hepatitis C 206 10.2.2.2.1 Favorable government initiatives to support growth 206 10.2.2.3 Other hepatitis diseases 209 10.2.3 RESPIRATORY INFECTIOUS DISEASES 212 10.2.3.1 Tuberculosis 216 10.2.3.1.1 Rising focus on reducing tuberculosis deaths to fuel market 216 10.2.3.2 Influenza 219 10.2.3.2.1 Growing strains and subtypes to drive market 219 10.2.3.3 Pharyngitis 222 10.2.3.3.1 Need to differentiate between bacterial and viral infections to fuel growth 222 10.2.3.4 Other respiratory infectious diseases 225 10.2.4 HOSPITAL-ACQUIRED INFECTIONS 228 10.2.4.1 Booming geriatric population to aid growth 228 10.2.5 VECTOR-BORNE DISEASES 231 10.2.5.1 Growing focus on disease surveillance to propel market 231 10.2.6 OTHER INFECTIOUS DISEASES 234 10.3 ONCOLOGY TESTING 238 10.3.1 BREAST CANCER 242 10.3.1.1 Increasing need to improve survival rates to support growth 242 10.3.2 COLORECTAL CANCER 245 10.3.2.1 Rising demand for biomarkers to fuel market 245 10.3.3 LUNG CANCER 247 10.3.3.1 Increasing use of predictive biomarkers to drive market 247 10.3.4 PROSTATE CANCER 250 10.3.4.1 Surge in advancements in genomic technologies to aid growth 250 10.3.5 OTHER CANCER TYPES 253 10.4 GENETIC TESTING 256 10.4.1 GROWING IMPORTANCE OF DIAGNOSING AND MANAGING RARE GENETIC DISEASES TO PROPEL MARKET 256 10.5 OTHER APPLICATIONS 259   11 MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE 262 11.1 INTRODUCTION 263 11.2 MULTIPLEX TESTING 263 11.2.1 RISING DEMAND FOR QUICK DIAGNOSIS TO PROMOTE GROWTH 263 11.3 SINGLEPLEX TESTING 267 11.3.1 NEED FOR AFFORDABLE TESTING TO AUGMENT GROWTH 267 12 MOLECULAR DIAGNOSTICS MARKET, BY CLINICAL APPLICATION 271 12.1 INTRODUCTION 272 12.2 DIAGNOSTIC 272 12.2.1 INCREASING CLINICAL NEED FOR CONFIRMATORY TESTING AND TIMELY TREATMENT TO DRIVE MARKET 272 12.3 SCREENING 275 12.3.1 GROWING IMPORTANCE OF EARLY INFECTIOUS DISEASE SCREENING TO PROPEL MARKET EXPANSION 275 13 MOLECULAR DIAGNOSTICS MARKET, BY END USER 279 13.1 INTRODUCTION 280 13.2 DIAGNOSTIC LABORATORIES 280 13.2.1 INCREASED OUTSOURCING OF LABORATORY DIAGNOSES FOR COST REDUCTION TO AID GROWTH 280 13.3 HOSPITALS & CLINICS 283 13.3.1 GROWING FOCUS ON HEALTHCARE SYSTEMS TO STIMULATE GROWTH 283 13.4 OTHER END USERS 286 14 MOLECULAR DIAGNOSTICS MARKET, BY REGION 290 14.1 INTRODUCTION 291 14.2 NORTH AMERICA 292 14.2.1 MACROECONOMIC OUTLOOK 299 14.2.2 US 300 14.2.2.1 Presence of advanced healthcare infrastructure and high healthcare expenditures to drive market 300 14.2.3 CANADA 305 14.2.3.1 Growing focus on genomic research to fuel market 305 14.3 EUROPE 310 14.3.1 MACROECONOMIC OUTLOOK 311 14.3.2 GERMANY 316 14.3.2.1 Robust healthcare spending and increasing per capita disposable income to propel market 316 14.3.3 UK 321 14.3.3.1 Expanding community-based diagnostics to drive adoption of molecular diagnostics 321   14.3.4 FRANCE 327 14.3.4.1 Rising R&D expenditure for product launches and development of new technologies to augment growth 327 14.3.5 ITALY 332 14.3.5.1 Growing demographic shift toward elderly population to support market 332 14.3.6 SPAIN 337 14.3.6.1 Surge in demand for genetic and prenatal testing to aid growth 337 14.3.7 RUSSIA 342 14.3.7.1 Increasing access to quality healthcare to boost market growth 342 14.3.8 SWITZERLAND 347 14.3.8.1 Rising healthcare spending for new medications and therapies to drive market 347 14.3.9 REST OF EUROPE 352 14.4 ASIA PACIFIC 357 14.4.1 MACROECONOMIC OUTLOOK 359 14.4.2 CHINA 363 14.4.2.1 Growing public access to modern healthcare to drive market 363 14.4.3 JAPAN 368 14.4.3.1 Universal healthcare reimbursement policy to support market 368 14.4.4 INDIA 373 14.4.4.1 Increasing penetration of medical insurance, hospital setups, and foreign direct investments to fuel market 373 14.4.5 AUSTRALIA 378 14.4.5.1 Rising technological advancements to stimulate growth 378 14.4.6 SOUTH KOREA 383 14.4.6.1 Favorable government initiatives for promoting medical tourism to support growth 383 14.4.7 REST OF ASIA PACIFIC 388 14.5 LATIN AMERICA 393 14.5.1 MACROECONOMIC OUTLOOK 394 14.5.2 BRAZIL 399 14.5.2.1 Universal healthcare access to drive adoption in Brazil 399 14.5.3 MEXICO 404 14.5.3.1 Booming medical tourism industry to aid growth 404 14.5.4 REST OF LATIN AMERICA 409 14.6 MIDDLE EAST & AFRICA 414 14.6.1 MACROECONOMIC OUTLOOK 415 14.6.2 SAUDI ARABIA 420 14.6.2.1 Rising government healthcare expenditure to boost market 420 14.6.3 UAE 425 14.6.3.1 Improvements in healthcare infrastructure to support growth 425 14.6.4 REST OF MIDDLE EAST & AFRICA 430 15 COMPETITIVE LANDSCAPE 436 15.1 INTRODUCTION 436 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 436 15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN MOLECULAR DIAGNOSTICS MARKET 436 15.3 REVENUE SHARE ANALYSIS 438 15.4 MARKET SHARE ANALYSIS, 2024 439 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 441 15.5.1 STARS 441 15.5.2 EMERGING LEADERS 441 15.5.3 PERVASIVE PLAYERS 441 15.5.4 PARTICIPANTS 441 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 443 15.5.5.1 Company footprint 443 15.5.5.2 Region footprint 443 15.5.5.3 Product & service footprint 444 15.5.5.4 Sample type footprint 444 15.5.5.5 Application footprint 445 15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 445 15.6.1 PROGRESSIVE COMPANIES 445 15.6.2 RESPONSIVE COMPANIES 445 15.6.3 DYNAMIC COMPANIES 446 15.6.4 STARTING BLOCKS 446 15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 447 15.6.5.1 Detailed list of key startups/SMES 447 15.6.5.2 Competitive benchmarking of startups/SMES 447 15.7 COMPANY VALUATION & FINANCIAL METRICS 448 15.7.1 FINANCIAL METRICS 448 15.7.2 COMPANY VALUATION 449 15.8 BRAND/PRODUCT COMPARISON 450 15.9 COMPETITIVE SCENARIO 450 15.9.1 PRODUCT/SERVICES LAUNCHES AND APPROVALS 450 15.9.2 DEALS 451 15.9.3 EXPANSIONS 452   16 COMPANY PROFILES 453 16.1 KEY PLAYERS 453 16.1.1 DANAHER CORPORATION 453 16.1.1.1 Business overview 453 16.1.1.2 Products/Services offered 454 16.1.1.3 Recent developments 456 16.1.1.3.1 Product/Service launches and approvals 456 16.1.1.3.2 Deals 457 16.1.1.3.3 Expansions 458 16.1.1.4 MnM view 458 16.1.1.4.1 Right to win 458 16.1.1.4.2 Strategic choices 458 16.1.1.4.3 Weaknesses and competitive threats 459 16.1.2 F. HOFFMANN-LA ROCHE LTD 460 16.1.2.1 Business overview 460 16.1.2.2 Products/Services offered 461 16.1.2.3 Recent developments 463 16.1.2.3.1 Product/Service launches and approvals 463 16.1.2.3.2 Deals 465 16.1.2.4 MnM view 466 16.1.2.4.1 Right to win 466 16.1.2.4.2 Strategic choices 466 16.1.2.4.3 Weaknesses and competitive threats 466 16.1.3 ILLUMINA, INC. 467 16.1.3.1 Business overview 467 16.1.3.2 Products/Services offered 468 16.1.3.3 Recent developments 469 16.1.3.3.1 Product/Service launches and approvals 469 16.1.3.3.2 Deals 470 16.1.3.3.3 Expansions 471 16.1.3.4 MnM view 471 16.1.3.4.1 Right to win 471 16.1.3.4.2 Strategic choices 472 16.1.3.4.3 Weaknesses and competitive threats 472 16.1.4 HOLOGIC, INC. 473 16.1.4.1 Business overview 473 16.1.4.2 Products/Services offered 474 16.1.4.3 Recent developments 475 16.1.4.3.1 Product/Service launches and approvals 475 16.1.4.3.2 Deals 476   16.1.4.4 MnM view 477 16.1.4.4.1 Right to win 477 16.1.4.4.2 Strategic choices 477 16.1.4.4.3 Weaknesses and competitive threats 477 16.1.5 BIOMÉRIEUX 478 16.1.5.1 Business overview 478 16.1.5.2 Products/Services offered 479 16.1.5.3 Recent developments 481 16.1.5.3.1 Product/Service launches and approvals 481 16.1.5.3.2 Deals 482 16.1.5.4 MnM view 483 16.1.5.4.1 Right to win 483 16.1.5.4.2 Strategic choices 483 16.1.5.4.3 Weaknesses and competitive threats 483 16.1.6 ABBOTT LABORATORIES 484 16.1.6.1 Business overview 484 16.1.6.2 Products/Services offered 485 16.1.6.3 Recent developments 487 16.1.6.3.1 Product/Service launches and approvals 487 16.1.6.3.2 Deals 488 16.1.7 THERMO FISHER SCIENTIFIC INC. 489 16.1.7.1 Business overview 489 16.1.7.2 Products/Services offered 490 16.1.7.3 Recent developments 491 16.1.7.3.1 Product/Service launches and approvals 491 16.1.7.3.2 Deals 492 16.1.8 QIAGEN N.V. 493 16.1.8.1 Business overview 493 16.1.8.2 Products/Services offered 494 16.1.8.3 Recent developments 496 16.1.8.3.1 Product/Service launches and approvals 496 16.1.8.3.2 Deals 498 16.1.8.3.3 Expansions 499 16.1.9 REVVITY, INC. 500 16.1.9.1 Business overview 500 16.1.9.2 Products/Services offered 501 16.1.10 MYRIAD GENETICS, INC. 502 16.1.10.1 Business overview 502 16.1.10.2 Products/Services offered 503 16.1.10.3 Recent developments 504 16.1.10.3.1 Product/Service launches and approvals 504 16.1.10.3.2 Deals 504 16.1.11 SIEMENS HEALTHINEERS AG 507 16.1.11.1 Business overview 507 16.1.11.2 Products/Services offered 508 16.1.11.3 Recent developments 509 16.1.11.3.1 Product/Service launches and approvals 509 16.1.11.3.2 Deals 509 16.1.11.3.3 Expansions 510 16.2 OTHER PLAYERS 511 16.2.1 BECTON, DICKINSON AND COMPANY (BD) 511 16.2.2 GRIFOLS, S.A. 512 16.2.3 QUIDELORTHO CORPORATION 513 16.2.4 DIASORIN S.P.A. 514 16.2.5 EXACT SCIENCES CORPORATION 516 16.2.6 GENETIC SIGNATURES 517 16.2.7 AGILENT TECHNOLOGIES, INC. 518 16.2.8 MDXHEALTH 519 16.2.9 BIOCARTIS 520 16.2.10 MEDIGEN BIOTECHNOLOGY CORP. 521 16.2.11 VELA DIAGNOSTICS 522 16.2.12 AMOY DIAGNOSTICS CO., LTD. 523 16.2.13 BRUKER CORPORATION (ELITECHGROUP) 524 16.2.14 MOLBIO DIAGNOSTICS LIMITED 526 16.2.15 GENEOMBIOTECHNOLOGIES 527 16.2.16 SAVYON DIAGNOSTICS 528 16.2.17 UNIOGEN OY 529 17 APPENDIX 530 17.1 DISCUSSION GUIDE 530 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 536 17.3 CUSTOMIZATION OPTIONS 538 17.4 RELATED REPORTS 538 17.5 AUTHOR DETAILS 539
圖表清單 List of Tables & Figures
TABLE 1 MOLECULAR DIAGNOSTICS MARKET: KEY DATA FROM PRIMARY SOURCES 56 TABLE 2 MOLECULAR DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS 65 TABLE 3 TYPES OF CANCER CASES WORLDWIDE, 2022 VS. 2045 81 TABLE 4 NUMBER OF CANCER PATIENTS WORLDWIDE, BY REGION, 2022 VS. 2035 VS. 2045 81 TABLE 5 AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTIC PRODUCTS, 2023–2025 (USD) 88 TABLE 6 AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTIC REAGENTS & KITS, BY KEY PLAYER, 2023–2025 (USD) 88 TABLE 7 AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTIC PRODUCTS, BY REGION, 2023–2025 (USD) 89 TABLE 8 LIST OF MAJOR PATENTS, 2022–2024 91 TABLE 9 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2020–2024 (USD MILLION) 95 TABLE 10 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2020–2024 (USD MILLION) 95 TABLE 11 MOLECULAR DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM 96 TABLE 12 IMPACT OF PORTER’S FORCES ON MOLECULAR DIAGNOSTICS MARKET 98 TABLE 13 CLASSIFICATION OF IVD DEVICES IN EUROPE 100 TABLE 14 TIME, COST, AND COMPLEXITY OF DEVICE REGISTRATION PROCESS IN JAPAN 102 TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 104 TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 104 TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 104 TABLE 18 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 105 TABLE 19 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 105 TABLE 20 MOLECULAR DIAGNOSTICS MARKET: KEY CONFERENCES & EVENTS, 2025–2026 108 TABLE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%) 110 TABLE 22 KEY BUYING CRITERIA, BY PRODUCT & SERVICE 110 TABLE 23 RECIPROCAL TARIFF RATES ADJUSTED BY US 116 TABLE 24 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 120 TABLE 25 KEY REAGENTS AND KITS AVAILABLE IN MARKET 121 TABLE 26 MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY REGION, 2023–2030 (USD MILLION) 122 TABLE 27 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 28 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 122 TABLE 29 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 123 TABLE 30 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 123 TABLE 31 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 123 TABLE 32 KEY INSTRUMENTS AVAILABLE IN MARKET 125 TABLE 33 MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2023–2030 (USD MILLION) 125 TABLE 34 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 35 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 126 TABLE 36 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 127 TABLE 37 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 127 TABLE 38 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 127 TABLE 39 KEY SOFTWARE SOLUTIONS AVAILABLE WORLDWIDE 128 TABLE 40 MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY REGION, 2023–2030 (USD MILLION) 129 TABLE 41 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 42 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 129 TABLE 43 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 130 TABLE 44 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 130 TABLE 45 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 130 TABLE 46 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 132 TABLE 47 KEY LABORATORY TESTING INSTRUMENTS AVAILABLE IN MARKET 133 TABLE 48 MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS, BY REGION, 2023–2030 (USD MILLION) 133 TABLE 49 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 50 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 134 TABLE 51 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 135 TABLE 52 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 135 TABLE 53 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 135 TABLE 54 KEY POC TESTING PRODUCTS AVAILABLE IN MARKET 137 TABLE 55 MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS, BY REGION, 2023–2030 (USD MILLION) 137 TABLE 56 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2023–2030 (USD MILLION) 137 TABLE 57 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 138 TABLE 58 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 138 TABLE 59 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 139 TABLE 60 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 139 TABLE 61 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 141 TABLE 62 KEY BLOOD, SERUM, AND PLASMA SAMPLE TYPE-BASED PRODUCTS AVAILABLE IN MARKET 142 TABLE 63 MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY REGION, 2023–2030 (USD MILLION) 143 TABLE 64 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 65 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 144 TABLE 66 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 144 TABLE 67 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 145 TABLE 68 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 145 TABLE 69 KEY URINE SAMPLE TYPE-BASED PRODUCTS AVAILABLE IN MARKET 146 TABLE 70 MOLECULAR DIAGNOSTICS MARKET FOR URINE, BY REGION, 2023–2030 (USD MILLION) 146 TABLE 71 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR URINE, BY COUNTRY, 2023–2030 (USD MILLION) 146 TABLE 72 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR URINE, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 147 TABLE 73 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR URINE, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 147 TABLE 74 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR URINE, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 148 TABLE 75 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR URINE, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 148 TABLE 76 OTHER SAMPLE TYPE-BASED PRODUCTS AVAILABLE IN MARKET 149 TABLE 77 MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2023–2030 (USD MILLION) 149 TABLE 78 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 79 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 150 TABLE 80 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 151 TABLE 81 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 151 TABLE 82 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 151 TABLE 83 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 153 TABLE 84 KEY POLYMERASE CHAIN REACTION INSTRUMENTS AVAILABLE IN MARKET 155 TABLE 85 MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023–2030 (USD MILLION) 155 TABLE 86 MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 156 TABLE 87 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 156 TABLE 88 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 156 TABLE 89 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 157 TABLE 90 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 157 TABLE 91 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 157 TABLE 92 KEY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY INSTRUMENTS AVAILABLE IN MARKET 158 TABLE 93 MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2023–2030 (USD MILLION) 159 TABLE 94 MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 159 TABLE 95 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 96 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 160 TABLE 97 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 160 TABLE 98 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 161 TABLE 99 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 161 TABLE 100 KEY NEXT-GENERATION SEQUENCING-BASED INSTRUMENTS AVAILABLE IN MARKET 162 TABLE 101 MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2023–2030 (USD MILLION) 162 TABLE 102 MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 163 TABLE 103 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 104 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 163 TABLE 105 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 164 TABLE 106 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 164 TABLE 107 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 164 TABLE 108 KEY IN SITU HYBRIDIZATION PRODUCTS AVAILABLE IN MARKET 165 TABLE 109 MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2023–2030 (USD MILLION) 166 TABLE 110 MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 166 TABLE 111 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 112 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 167 TABLE 113 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 167 TABLE 114 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 168 TABLE 115 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 168 TABLE 116 KEY MICROARRAY-BASED PRODUCTS AVAILABLE IN MARKET 169 TABLE 117 MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION, 2023–2030 (USD MILLION) 169 TABLE 118 MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 170 TABLE 119 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION) 170 TABLE 120 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 170 TABLE 121 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 171 TABLE 122 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 171 TABLE 123 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 171 TABLE 124 MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION) 173 TABLE 125 MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 173 TABLE 126 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 173 TABLE 127 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 174 TABLE 128 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 174 TABLE 129 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 175 TABLE 130 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 175 TABLE 131 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 177 TABLE 132 KEY INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET 178 TABLE 133 MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2023–2030 (USD MILLION) 179 TABLE 134 MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION) 179 TABLE 135 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 179 TABLE 136 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 180 TABLE 137 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 180 TABLE 138 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 181 TABLE 139 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 181 TABLE 140 MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY REGION, 2023–2030 (USD MILLION) 182 TABLE 141 MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION) 182 TABLE 142 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 183 TABLE 143 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 183 TABLE 144 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 184 TABLE 145 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 184 TABLE 146 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 184 TABLE 147 KEY CT/NG MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET 185 TABLE 148 MOLECULAR DIAGNOSTICS MARKET FOR CT/NG, BY REGION, 2023–2030 (USD MILLION) 186 TABLE 149 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR CT/NG, BY COUNTRY, 2023–2030 (USD MILLION) 186 TABLE 150 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR CT/NG, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 186 TABLE 151 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET CT/NG, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 187 TABLE 152 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR CT/NG, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 187 TABLE 153 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR CT/NG, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 187 TABLE 154 KEY HIV MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET 188 TABLE 155 MOLECULAR DIAGNOSTICS MARKET FOR HIV, BY REGION, 2023–2030 (USD MILLION) 189 TABLE 156 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2023–2030 (USD MILLION) 189 TABLE 157 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HIV, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 189 TABLE 158 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET HIV, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 190 TABLE 159 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HIV, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 190 TABLE 160 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HIV, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 190 TABLE 161 KEY HPV MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET 191 TABLE 162 MOLECULAR DIAGNOSTICS MARKET FOR HPV, BY REGION, 2023–2030 (USD MILLION) 192 TABLE 163 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2023–2030 (USD MILLION) 192 TABLE 164 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HPV, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 192 TABLE 165 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET HPV, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 193 TABLE 166 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HPV, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 193 TABLE 167 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HPV, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 193 TABLE 168 KEY SYPHILIS MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET 194 TABLE 169 MOLECULAR DIAGNOSTICS MARKET FOR SYPHILIS, BY REGION, 2023–2030 (USD MILLION) 195 TABLE 170 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY, 2023–2030 (USD MILLION) 195 TABLE 171 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 195 TABLE 172 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 196 TABLE 173 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 196 TABLE 174 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 196 TABLE 175 OTHER SEXUALLY TRANSMITTED DISEASE MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET 197 TABLE 176 MOLECULAR DIAGNOSTICS MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY REGION, 2023–2030 (USD MILLION) 198 TABLE 177 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 198 TABLE 178 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 198 TABLE 179 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 199 TABLE 180 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 199 TABLE 181 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 199 TABLE 182 KEY HEPATITIS MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET 200 TABLE 183 MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2023–2030 (USD MILLION) 201 TABLE 184 MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 201 TABLE 185 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION) 201 TABLE 186 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 202 TABLE 187 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 202 TABLE 188 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 203 TABLE 189 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 203 TABLE 190 MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS B, BY REGION, 2023–2030 (USD MILLION) 204 TABLE 191 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2023–2030 (USD MILLION) 204 TABLE 192 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 205 TABLE 193 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 205 TABLE 194 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 206 TABLE 195 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 206 TABLE 196 MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS C, BY REGION, 2023–2030 (USD MILLION) 207 TABLE 197 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2023–2030 (USD MILLION) 207 TABLE 198 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 208 TABLE 199 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 208 TABLE 200 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 209 TABLE 201 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 209 TABLE 202 MOLECULAR DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY REGION, 2023–2030 (USD MILLION) 210 TABLE 203 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 210 TABLE 204 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 211 TABLE 205 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 211 TABLE 206 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 212 TABLE 207 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 212 TABLE 208 MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2023–2030 (USD MILLION) 213 TABLE 209 MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY TYPE, 2023–2030 (USD MILLION) 213 TABLE 210 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 214 TABLE 211 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 214 TABLE 212 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 215 TABLE 213 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 215 TABLE 214 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 215 TABLE 215 KEY TUBERCULOSIS MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET 216 TABLE 216 MOLECULAR DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY REGION, 2023–2030 (USD MILLION) 217 TABLE 217 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2023–2030 (USD MILLION) 217 TABLE 218 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 217 TABLE 219 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 218 TABLE 220 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 218 TABLE 221 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 218 TABLE 222 GLOBAL NUMBER OF NEWLY DIAGNOSED TUBERCULOSIS (TB) CASES, 2023–2030 (MILLIONS) 219 TABLE 223 KEY INFLUENZA MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET 219 TABLE 224 MOLECULAR DIAGNOSTICS MARKET FOR INFLUENZA, BY REGION, 2023–2030 (USD MILLION) 220 TABLE 225 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2023–2030 (USD MILLION) 220 TABLE 226 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 220 TABLE 227 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 221 TABLE 228 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 221 TABLE 229 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 221 TABLE 230 KEY PHARYNGITIS MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET 222 TABLE 231 MOLECULAR DIAGNOSTICS MARKET FOR PHARYNGITIS, BY REGION, 2023–2030 (USD MILLION) 223 TABLE 232 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR PHARYNGITIS, BY COUNTRY, 2023–2030 (USD MILLION) 223 TABLE 233 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR PHARYNGITIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 223 TABLE 234 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR PHARYNGITIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 224 TABLE 235 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR PHARYNGITIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 224 TABLE 236 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR PHARYNGITIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 224 TABLE 237 OTHER RESPIRATORY INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET 225 TABLE 238 MOLECULAR DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION) 226 TABLE 239 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 226 TABLE 240 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 226 TABLE 241 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 227 TABLE 242 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 227 TABLE 243 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 227 TABLE 244 KEY HOSPITAL-ACQUIRED INFECTION-BASED MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET 228 TABLE 245 MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2023–2030 (USD MILLION) 229 TABLE 246 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION) 229 TABLE 247 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 229 TABLE 248 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 230 TABLE 249 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 230 TABLE 250 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 230 TABLE 251 KEY VECTOR-BORNE DISEASES DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET 231 TABLE 252 MOLECULAR DIAGNOSTICS MARKET FOR VECTOR-BORNE DISEASES, BY REGION, 2023–2030 (USD MILLION) 232 TABLE 253 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 232 TABLE 254 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 232 TABLE 255 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET VECTOR-BORNE DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 233 TABLE 256 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 233 TABLE 257 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 233 TABLE 258 GLOBAL CASES OF ACTIVE SYPHILIS IN AGE GROUP FROM 15 TO 49 YEARS, 2016–2022 (THOUSANDS) 234 TABLE 259 OTHER INFECTIOUS DISEASE MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET 235 TABLE 260 MOLECULAR DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION) 235 TABLE 261 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 236 TABLE 262 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 236 TABLE 263 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 237 TABLE 264 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 237 TABLE 265 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 237 TABLE 266 KEY ONCOLOGY TESTING PRODUCTS AVAILABLE IN MARKET 239 TABLE 267 MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY REGION, 2023–2030 (USD MILLION) 239 TABLE 268 MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION) 240 TABLE 269 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY, 2023–2030 (USD MILLION) 240 TABLE 270 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 240 TABLE 271 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 241 TABLE 272 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 241 TABLE 273 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 241 TABLE 274 BREAST CANCER INCIDENCE, BY REGION, 2022 VS. 2030 242 TABLE 275 MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2023–2030 (USD MILLION) 243 TABLE 276 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 243 TABLE 277 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 243 TABLE 278 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 244 TABLE 279 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 244 TABLE 280 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 244 TABLE 281 COLORECTAL CANCER INCIDENCE, BY REGION, 2022 VS. 2030 245 TABLE 282 MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY REGION, 2023–2030 (USD MILLION) 245 TABLE 283 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 246 TABLE 284 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 246 TABLE 285 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 246 TABLE 286 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 247 TABLE 287 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 247 TABLE 288 LUNG CANCER INCIDENCE, BY REGION, 2022 VS. 2030 248 TABLE 289 MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER, BY REGION, 2023–2030 (USD MILLION) 248 TABLE 290 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 248 TABLE 291 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 249 TABLE 292 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 249 TABLE 293 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 250 TABLE 294 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 250 TABLE 295 PROSTATE CANCER INCIDENCE, BY REGION, 2022 VS. 2030 251 TABLE 296 MOLECULAR DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY REGION, 2023–2030 (USD MILLION) 251 TABLE 297 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 251 TABLE 298 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 252 TABLE 299 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 252 TABLE 300 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 253 TABLE 301 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 253 TABLE 302 GLOBAL INCIDENCE OF OTHER CANCER TYPES, 2022 VS. 2030 253 TABLE 303 MOLECULAR DIAGNOSTICS MARKET FOR OTHER CANCER TYPES, BY REGION, 2023–2030 (USD MILLION) 254 TABLE 304 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER CANCER TYPES, BY COUNTRY, 2023–2030 (USD MILLION) 254 TABLE 305 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER CANCER TYPES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 255 TABLE 306 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER CANCER TYPES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 255 TABLE 307 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER CANCER TYPES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 256 TABLE 308 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER CANCER TYPES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 256 TABLE 309 KEY GENETIC TESTING PRODUCTS AVAILABLE IN MARKET 257 TABLE 310 MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING, BY REGION, 2023–2030 (USD MILLION) 257 TABLE 311 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2023–2030 (USD MILLION) 257 TABLE 312 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 258 TABLE 313 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 258 TABLE 314 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 259 TABLE 315 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 259 TABLE 316 MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 260 TABLE 317 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 260 TABLE 318 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 260 TABLE 319 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 261 TABLE 320 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 261 TABLE 321 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 261 TABLE 322 MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 263 TABLE 323 KEY MULTIPLEX TESTING PRODUCTS AVAILABLE IN MARKET 264 TABLE 324 MOLECULAR DIAGNOSTICS MARKET FOR MULTIPLEX TESTING, BY REGION, 2023–2030 (USD MILLION) 264 TABLE 325 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR MULTIPLEX TESTING, BY COUNTRY, 2023–2030 (USD MILLION) 265 TABLE 326 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR MULTIPLEX TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 265 TABLE 327 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR MULTIPLEX TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 266 TABLE 328 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR MULTIPLEX TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 266 TABLE 329 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR MULTIPLEX TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 266 TABLE 330 KEY SINGLEPLEX TESTING PRODUCTS AVAILABLE IN MARKET 267 TABLE 331 MOLECULAR DIAGNOSTICS MARKET FOR SINGLEPLEX TESTING, BY REGION, 2023–2030 (USD MILLION) 268 TABLE 332 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SINGLEPLEX TESTING, BY COUNTRY, 2023–2030 (USD MILLION) 268 TABLE 333 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR SINGLEPLEX TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 269 TABLE 334 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR SINGLEPLEX TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 269 TABLE 335 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SINGLEPLEX TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 270 TABLE 336 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR SINGLEPLEX TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 270 TABLE 337 MOLECULAR DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 272 TABLE 338 KEY DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET 273 TABLE 339 MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC, BY REGION, 2023–2030 (USD MILLION) 273 TABLE 340 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC, BY COUNTRY, 2023–2030 (USD MILLION) 273 TABLE 341 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 274 TABLE 342 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 274 TABLE 343 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 275 TABLE 344 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 275 TABLE 345 KEY SCREENING PRODUCTS AVAILABLE IN MARKET 276 TABLE 346 MOLECULAR DIAGNOSTICS MARKET FOR SCREENING, BY REGION, 2023–2030 (USD MILLION) 276 TABLE 347 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 276 TABLE 348 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 277 TABLE 349 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 277 TABLE 350 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 278 TABLE 351 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 278 TABLE 352 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 280 TABLE 353 MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION) 281 TABLE 354 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 281 TABLE 355 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 282 TABLE 356 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 282 TABLE 357 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 283 TABLE 358 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 283 TABLE 359 MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023–2030 (USD MILLION) 284 TABLE 360 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 285 TABLE 361 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 285 TABLE 362 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 285 TABLE 363 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 286 TABLE 364 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 286 TABLE 365 MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 287 TABLE 366 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 287 TABLE 367 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 288 TABLE 368 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 288 TABLE 369 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 289 TABLE 370 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 289 TABLE 371 PROJECTED CANCER CASES, BY COUNTRY, 2030 291 TABLE 372 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2023–2030 (USD MILLION) 292 TABLE 373 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 294 TABLE 374 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 295 TABLE 375 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 295 TABLE 376 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 295 TABLE 377 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 296 TABLE 378 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 296 TABLE 379 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION) 297 TABLE 380 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 297 TABLE 381 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION) 298 TABLE 382 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 298 TABLE 383 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION) 298 TABLE 384 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 299 TABLE 385 NORTH AMERICA: MACROECONOMIC INDICATORS 299 TABLE 386 US: CANCER CASES AND MORTALITY, BY CANCER TYPE, 2022 VS. 2030 300 TABLE 387 US: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 301 TABLE 388 US: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 301 TABLE 389 US: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 301 TABLE 390 US: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 302 TABLE 391 US: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 302 TABLE 392 US: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION) 303 TABLE 393 US: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 303 TABLE 394 US: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION) 303 TABLE 395 US: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 304 TABLE 396 US: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION) 304 TABLE 397 US: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 304 TABLE 398 CANADA: PROJECTED CANCER CASES, BY TYPE, 2030 305 TABLE 399 CANADA: FIVE COMMON CANCER TYPES AND DEATH PERCENTAGE 305 TABLE 400 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 306 TABLE 401 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 307 TABLE 402 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 307 TABLE 403 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 307 TABLE 404 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 308 TABLE 405 CANADA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION) 308 TABLE 406 CANADA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 308 TABLE 407 CANADA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION) 309 TABLE 408 CANADA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 309 TABLE 409 CANADA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION) 309 TABLE 410 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 310 TABLE 411 EUROPE: MACROECONOMIC INDICATORS 311 TABLE 412 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 311 TABLE 413 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 312 TABLE 414 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 312 TABLE 415 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 312 TABLE 416 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 313 TABLE 417 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 313 TABLE 418 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION) 314 TABLE 419 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 314 TABLE 420 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION) 315 TABLE 421 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 315 TABLE 422 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION) 315 TABLE 423 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 316 TABLE 424 GERMANY: PROJECTED CANCER CASES, BY TYPE, 2030 316 TABLE 425 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 317 TABLE 426 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 318 TABLE 427 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 318 TABLE 428 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 318 TABLE 429 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 319 TABLE 430 GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION) 319 TABLE 431 GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 319 TABLE 432 GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION) 320 TABLE 433 GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 320 TABLE 434 GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION) 320 TABLE 435 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 321 TABLE 436 UK: PROJECTED CANCER CASES, BY TYPE, 2030 322 TABLE 437 UK: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 323 TABLE 438 UK: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 323 TABLE 439 UK: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 323 TABLE 440 UK: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 324 TABLE 441 UK: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 324 TABLE 442 UK: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION) 325 TABLE 443 UK: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 325 TABLE 444 UK: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION) 326 TABLE 445 UK: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 326 TABLE 446 UK: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION) 326 TABLE 447 UK: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 327 TABLE 448 FRANCE: PROJECTED CANCER CASES, BY TYPE, 2030 328 TABLE 449 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 328 TABLE 450 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 328 TABLE 451 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 329 TABLE 452 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 329 TABLE 453 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 329 TABLE 454 FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION) 330 TABLE 455 FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 330 TABLE 456 FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION) 330 TABLE 457 FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 331 TABLE 458 FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION) 331 TABLE 459 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 331 TABLE 460 ITALY: PROJECTED CANCER CASES, BY TYPE, 2030 333 TABLE 461 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 333 TABLE 462 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 333 TABLE 463 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 334 TABLE 464 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 334 TABLE 465 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 334 TABLE 466 ITALY: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION) 335 TABLE 467 ITALY: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 335 TABLE 468 ITALY: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION) 335 TABLE 469 ITALY: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 336 TABLE 470 ITALY: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION) 336 TABLE 471 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 336 TABLE 472 SPAIN: PROJECTED CANCER CASES, BY TYPE, 2030 337 TABLE 473 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 338 TABLE 474 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 338 TABLE 475 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 338 TABLE 476 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 339 TABLE 477 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 339 TABLE 478 SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION) 340 TABLE 479 SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 340 TABLE 480 SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION) 341 TABLE 481 SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 341 TABLE 482 SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION) 341 TABLE 483 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 342 TABLE 484 RUSSIA: PROJECTED CANCER CASES, BY TYPE, 2030 343 TABLE 485 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 343 TABLE 486 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 343 TABLE 487 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 344 TABLE 488 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 344 TABLE 489 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 344 TABLE 490 RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION) 345 TABLE 491 RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 345 TABLE 492 RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION) 346 TABLE 493 RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 346 TABLE 494 RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION) 346 TABLE 495 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 347 TABLE 496 SWITZERLAND: PROJECTED CANCER CASES, BY TYPE, 2030 348 TABLE 497 SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 348 TABLE 498 SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 348 TABLE 499 SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 349 TABLE 500 SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 349 TABLE 501 SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 349 TABLE 502 SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION) 350 TABLE 503 SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 350 TABLE 504 SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION) 351 TABLE 505 SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 351 TABLE 506 SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION) 351 TABLE 507 SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 352 TABLE 508 REST OF EUROPE: PROJECTED CANCER CASES, BY COUNTRY, 2030 352 TABLE 509 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 353 TABLE 510 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 353 TABLE 511 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 353 TABLE 512 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 354 TABLE 513 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 354 TABLE 514 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION) 355 TABLE 515 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 355 TABLE 516 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION) 356 TABLE 517 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 356 TABLE 518 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION) 356 TABLE 519 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 357 TABLE 520 ASIA PACIFIC: MACROECONOMIC INDICATORS 358 TABLE 521 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 359 TABLE 522 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 359 TABLE 523 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 360 TABLE 524 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 360 TABLE 525 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 360 TABLE 526 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 361 TABLE 527 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION) 361 TABLE 528 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 361 TABLE 529 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION) 362 TABLE 530 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 362 TABLE 531 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION) 362 TABLE 532 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 363 TABLE 533 CHINA: PROJECTED CANCER CASES, BY TYPE, 2030 364 TABLE 534 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 364 TABLE 535 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 364 TABLE 536 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 365 TABLE 537 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 365 TABLE 538 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 365 TABLE 539 CHINA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION) 366 TABLE 540 CHINA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 366 TABLE 541 CHINA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION) 366 TABLE 542 CHINA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 367 TABLE 543 CHINA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION) 367 TABLE 544 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 367 TABLE 545 JAPAN: PROJECTED CANCER CASES, BY TYPE, 2030 369 TABLE 546 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 369 TABLE 547 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 369 TABLE 548 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 370 TABLE 549 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 370 TABLE 550 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 370 TABLE 551 JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION) 371 TABLE 552 JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 371 TABLE 553 JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION) 371 TABLE 554 JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 372 TABLE 555 JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION) 372 TABLE 556 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 372 TABLE 557 INDIA: PROJECTED CANCER CASES, BY TYPE, 2030 374 TABLE 558 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 374 TABLE 559 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 375 TABLE 560 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 375 TABLE 561 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 375 TABLE 562 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 376 TABLE 563 INDIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION) 376 TABLE 564 INDIA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 376 TABLE 565 INDIA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION) 377 TABLE 566 INDIA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 377 TABLE 567 INDIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION) 377 TABLE 568 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 378 TABLE 569 AUSTRALIA: PROJECTED CANCER CASES, BY TYPE, 2030 379 TABLE 570 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 379 TABLE 571 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 379 TABLE 572 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 380 TABLE 573 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 380 TABLE 574 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 380 TABLE 575 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION) 381 TABLE 576 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 381 TABLE 577 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION) 382 TABLE 578 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 382 TABLE 579 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION) 382 TABLE 580 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 383 TABLE 581 SOUTH KOREA: PROJECTED CANCER CASES, BY TYPE, 2030 384 TABLE 582 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 384 TABLE 583 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 384 TABLE 584 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 385 TABLE 585 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 385 TABLE 586 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 385 TABLE 587 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION) 386 TABLE 588 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 386 TABLE 589 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION) 387 TABLE 590 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 387 TABLE 591 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION) 387 TABLE 592 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 388 TABLE 593 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 389 TABLE 594 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 389 TABLE 595 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 389 TABLE 596 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 390 TABLE 597 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 390 TABLE 598 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION) 391 TABLE 599 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 391 TABLE 600 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION) 392 TABLE 601 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 392 TABLE 602 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION) 392 TABLE 603 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 393 TABLE 604 LATIN AMERICA: MACROECONOMIC INDICATORS 394 TABLE 605 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 394 TABLE 606 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 395 TABLE 607 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 395 TABLE 608 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 395 TABLE 609 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 396 TABLE 610 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 396 TABLE 611 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION) 397 TABLE 612 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 397 TABLE 613 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION) 398 TABLE 614 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 398 TABLE 615 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION) 398 TABLE 616 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 399 TABLE 617 BRAZIL: PROJECTED CANCER CASES, BY TYPE, 2030 400 TABLE 618 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 400 TABLE 619 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 400 TABLE 620 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 401 TABLE 621 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 401 TABLE 622 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 401 TABLE 623 BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION) 402 TABLE 624 BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 402 TABLE 625 BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION) 403 TABLE 626 BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 403 TABLE 627 BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION) 403 TABLE 628 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 404 TABLE 629 MEXICO: PROJECTED CANCER CASES, BY TYPE, 2030 405 TABLE 630 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 405 TABLE 631 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 405 TABLE 632 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 406 TABLE 633 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 406 TABLE 634 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 406 TABLE 635 MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION) 407 TABLE 636 MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 407 TABLE 637 MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION) 408 TABLE 638 MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 408 TABLE 639 MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION) 408 TABLE 640 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 409 TABLE 641 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 410 TABLE 642 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 410 TABLE 643 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 410 TABLE 644 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 411 TABLE 645 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 411 TABLE 646 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION) 412 TABLE 647 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 412 TABLE 648 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION) 413 TABLE 649 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 413 TABLE 650 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION) 413 TABLE 651 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 414 TABLE 652 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 415 TABLE 653 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 415 TABLE 654 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 416 TABLE 655 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 416 TABLE 656 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 416 TABLE 657 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 417 TABLE 658 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 417 TABLE 659 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION) 418 TABLE 660 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 418 TABLE 661 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION) 419 TABLE 662 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 419 TABLE 663 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION) 419 TABLE 664 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 420 TABLE 665 SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 421 TABLE 666 SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 421 TABLE 667 SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 421 TABLE 668 SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 422 TABLE 669 SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 422 TABLE 670 SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION) 423 TABLE 671 SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 423 TABLE 672 SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION) 424 TABLE 673 SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 424 TABLE 674 SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION) 424 TABLE 675 SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 425 TABLE 676 UAE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 426 TABLE 677 UAE: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 426 TABLE 678 UAE: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 426 TABLE 679 UAE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 427 TABLE 680 UAE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 427 TABLE 681 UAE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION) 428 TABLE 682 UAE: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 428 TABLE 683 UAE: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION) 429 TABLE 684 UAE: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 429 TABLE 685 UAE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION) 429 TABLE 686 UAE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 430 TABLE 687 REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 431 TABLE 688 REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 431 TABLE 689 REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 431 TABLE 690 REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 432 TABLE 691 REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 432 TABLE 692 REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION) 433 TABLE 693 REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 433 TABLE 694 REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION) 434 TABLE 695 REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 434 TABLE 696 REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION) 434 TABLE 697 REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 435 TABLE 698 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS, JANUARY 2021−JULY 2025 436 TABLE 699 MOLECULAR DIAGNOSTICS MARKET: DEGREE OF COMPETITION 439 TABLE 700 MOLECULAR DIAGNOSTICS MARKET: REGION FOOTPRINT 443 TABLE 701 MOLECULAR DIAGNOSTICS MARKET: PRODUCT & SERVICE FOOTPRINT 444 TABLE 702 MOLECULAR DIAGNOSTICS MARKET: SAMPLE TYPE FOOTPRINT 444 TABLE 703 MOLECULAR DIAGNOSTICS MARKET: APPLICATION FOOTPRINT 445 TABLE 704 MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 447 TABLE 705 MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2) 447 TABLE 706 MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2) 448 TABLE 707 MOLECULAR DIAGNOSTICS MARKET: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021–JULY 2025 450 TABLE 708 MOLECULAR DIAGNOSTICS MARKET: DEALS, JANUARY 2021–JULY 2025 451 TABLE 709 MOLECULAR DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2021– JULY 2025 452 TABLE 710 DANAHER CORPORATION: COMPANY OVERVIEW 453 TABLE 711 DANAHER CORPORATION: PRODUCTS/SERVICES OFFERED 454 TABLE 712 DANAHER CORPORATION: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021–JULY 2025 456 TABLE 713 DANAHER CORPORATION: DEALS, JANUARY 2021–JULY 2025 457 TABLE 714 DANAHER CORPORATION: EXPANSIONS, JANUARY 2021–JULY 2025 458 TABLE 715 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW 460 TABLE 716 F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SERVICES OFFERED 461 TABLE 717 F. HOFFMANN-LA ROCHE LTD: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021–JULY 2025 463 TABLE 718 F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2021–JULY 2025 465 TABLE 719 ILLUMINA, INC.: COMPANY OVERVIEW 467 TABLE 720 ILLUMINA, INC.: PRODUCTS/SERVICES OFFERED 468 TABLE 721 ILLUMINA, INC.: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021–JULY 2025 469 TABLE 722 ILLUMINA, INC.: DEALS, JANUARY 2021– JULY 2025 470 TABLE 723 ILLUMINA, INC.: EXPANSIONS, JANUARY 2021–JULY 2025 471 TABLE 724 HOLOGIC, INC.: COMPANY OVERVIEW 473 TABLE 725 HOLOGIC, INC.: PRODUCTS/SERVICES OFFERED 474 TABLE 726 HOLOGIC, INC.: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021–JULY 2025 475 TABLE 727 HOLOGIC, INC.: DEALS, JANUARY 2021– JULY 2025 476 TABLE 728 BIOMÉRIEUX: COMPANY OVERVIEW 478 TABLE 729 BIOMÉRIEUX: PRODUCTS/SERVICES OFFERED 479 TABLE 730 BIOMÉRIEUX: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021–JULY 2025 481 TABLE 731 BIOMÉRIEUX: DEALS, JANUARY 2021– JULY 2025 482 TABLE 732 ABBOTT LABORATORIES: COMPANY OVERVIEW 484 TABLE 733 ABBOTT LABORATORIES: PRODUCTS/SERVICES OFFERED 485 TABLE 734 ABBOTT LABORATORIES: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021–JULY 2025 487 TABLE 735 ABBOTT LABORATORIES: DEALS, JANUARY 2021– JULY 2025 488 TABLE 736 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 489 TABLE 737 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED 490 TABLE 738 THERMO FISHER SCIENTIFIC INC.: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021–JULY 2025 491 TABLE 739 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021– JULY 2025 492 TABLE 740 QIAGEN N.V.: COMPANY OVERVIEW 493 TABLE 741 QIAGEN N.V.: PRODUCTS/SERVICES OFFERED 494 TABLE 742 QIAGEN N.V.: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021–JULY 2025 496 TABLE 743 QIAGEN N.V.: DEALS, JANUARY 2021– JULY 2025 498 TABLE 744 QIAGEN N.V.: EXPANSIONS, JANUARY 2021–JULY 2025 499 TABLE 745 REVVITY, INC.: COMPANY OVERVIEW 500 TABLE 746 REVVITY, INC.: PRODUCTS/SERVICES OFFERED 501 TABLE 747 MYRIAD GENETICS, INC.: COMPANY OVERVIEW 502 TABLE 748 MYRIAD GENETICS, INC.: PRODUCTS/SERVICES OFFERED 503 TABLE 749 MYRIAD GENETICS, INC.: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021–JULY 2025 504 TABLE 750 MYRIAD GENETICS, INC.: DEALS, JANUARY 2021- JULY 2025 504 TABLE 751 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 507 TABLE 752 SIEMENS HEALTHINEERS AG: PRODUCTS/SERVICES OFFERED 508 TABLE 753 SIEMENS HEALTHINEERS AG: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021–JULY 2025 509 TABLE 754 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021– JULY 2025 509 TABLE 755 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2021– JULY 2025 510 TABLE 756 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW 511 TABLE 757 GRIFOLS, S.A.: COMPANY OVERVIEW 512 TABLE 758 QUIDELORTHO CORPORATION: COMPANY OVERVIEW 513 TABLE 759 DIASORIN S.P.A.: COMPANY OVERVIEW 514 TABLE 760 EXACT SCIENCES CORPORATION: COMPANY OVERVIEW 516 TABLE 761 GENETIC SIGNATURES: COMPANY OVERVIEW 517 TABLE 762 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 518 TABLE 763 MDXHEALTH: COMPANY OVERVIEW 519 TABLE 764 BIOCARTIS: COMPANY OVERVIEW 520 TABLE 765 MEDIGEN BIOTECHNOLOGY CORP.: COMPANY OVERVIEW 521 TABLE 766 VELA DIAGNOSTICS: COMPANY OVERVIEW 522 TABLE 767 AMOY DIAGNOSTICS CO., LTD.: COMPANY OVERVIEW 523 TABLE 768 BRUKER CORPORATION (ELITECHGROUP): COMPANY OVERVIEW 524 TABLE 769 MOLBIO DIAGNOSTICS LIMITED: COMPANY OVERVIEW 526 TABLE 770 GENEOMBIOTECHNOLOGIES: COMPANY OVERVIEW 527 TABLE 771 SAVYON DIAGNOSTICS: COMPANY OVERVIEW 528 TABLE 772 UNIOGEN OY: COMPANY OVERVIEW 529 FIGURE 1 RESEARCH DESIGN METHODOLOGY 53 FIGURE 2 KEY PRIMARY SOURCES 56 FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 59 FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 59 FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 60 FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 61 FIGURE 7 MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH 62 FIGURE 8 DATA TRIANGULATION METHODOLOGY 63 FIGURE 9 MOLECULAR DIAGNOSTICS MARKET: RESEARCH ASSUMPTIONS 64 FIGURE 10 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION) 66 FIGURE 11 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2025 VS. 2030 (USD MILLION) 67 FIGURE 12 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2025 VS. 2030 (USD MILLION) 67 FIGURE 13 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION) 68 FIGURE 14 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 69 FIGURE 15 MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2025 VS. 2030 (USD MILLION) 70 FIGURE 16 MOLECULAR DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2025 VS. 2030 (USD MILLION) 70 FIGURE 17 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 71 FIGURE 18 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2025 VS. 2030 (USD MILLION) 72 FIGURE 19 INCREASING PREVALENCE OF INFECTIOUS DISEASES AND CANCER TO DRIVE MARKET 73 FIGURE 20 REAGENTS & KITS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 73 FIGURE 21 LAB TESTS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 74 FIGURE 22 BLOOD, SERUM, AND PLASMA SEGMENT TO ACCOUNT FOR LARGEST SHARE DURING FORECAST PERIOD 74 FIGURE 23 POLYMERASE CHAIN REACTION SEGMENT TO ACHIEVE LARGEST SHARE DURING FORECAST PERIOD 75 FIGURE 24 INFECTIOUS DISEASE DIAGNOSTICS SEGMENT TO ACCOUNT FOR LARGEST SHARE DURING FORECAST PERIOD 75 FIGURE 25 MULTIPLEX TESTING SEGMENT TO ACCOUNT FOR SIGNIFICANT SHARE DURING FORECAST PERIOD 76 FIGURE 26 DIAGNOSTIC SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 76 FIGURE 27 DIAGNOSTIC LABORATORIES SEGMENT TO LEAD MARKET IN 2030 77 FIGURE 28 NORTH AMERICA TO ACCOUNT FOR LARGEST SHARE DURING FORECAST PERIOD 77 FIGURE 29 MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 78 FIGURE 30 INCIDENCE OF HIV, BY REGION, 2024 80 FIGURE 31 PATENT ANALYSIS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES, JANUARY 2015–DECEMBER 2024 90 FIGURE 32 MOLECULAR DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS 92 FIGURE 33 MOLECULAR DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS 94 FIGURE 34 MOLECULAR DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS 96 FIGURE 35 MOLECULAR DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 97 FIGURE 36 MOLECULAR DIAGNOSTICS MARKET: TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS 109 FIGURE 37 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE 109 FIGURE 38 KEY BUYING CRITERIA, BY PRODUCT & SERVICE 110 FIGURE 39 NUMBER OF DEALS & TOTAL FUNDING, 2021–2025 111 FIGURE 40 MOLECULAR DIAGNOSTICS MARKET: KEY USE CASES 113 FIGURE 41 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT 294 FIGURE 42 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT 358 FIGURE 43 REVENUE ANALYSIS OF KEY PLAYERS, 2022–2024 (USD MILLION) 438 FIGURE 44 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024 439 FIGURE 45 MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 442 FIGURE 46 MOLECULAR DIAGNOSTICS MARKET: COMPANY FOOTPRINT 443 FIGURE 47 MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 446 FIGURE 48 EV/EBITDA OF KEY VENDORS 448 FIGURE 49 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 449 FIGURE 50 BRAND/PRODUCT COMPARISON FOR MOLECULAR DIAGNOSTIC INSTRUMENTS 450 FIGURE 51 DANAHER CORPORATION: COMPANY SNAPSHOT (2024) 454 FIGURE 52 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024) 461 FIGURE 53 ILLUMINA, INC.: COMPANY SNAPSHOT (2024) 468 FIGURE 54 HOLOGIC, INC.: COMPANY SNAPSHOT (2024) 474 FIGURE 55 BIOMÉRIEUX: COMPANY SNAPSHOT (2024) 479 FIGURE 56 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2024) 485 FIGURE 57 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024) 490 FIGURE 58 QIAGEN N.V.: COMPANY SNAPSHOT (2024) 494 FIGURE 59 REVVITY, INC.: COMPANY SNAPSHOT (2024) 501 FIGURE 60 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2024) 503 FIGURE 61 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024) 508

同分類最新報告（醫療器材）

查看醫療器材全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們